Universal Health (UHS) stock is soaring 5.15% in Tuesday's intraday trading, buoyed by a series of positive analyst reports and price target adjustments. The healthcare services provider is seeing renewed investor confidence as multiple financial institutions reaffirm their bullish stance on the company's prospects.

TD Cowen analyst Ryan Langston reiterated a Buy rating on Universal Health, setting a price target of $226.00. This vote of confidence was echoed by Barclays, which raised its price target to $259 from $257, underlining the firm's optimistic view on UHS's future performance. Meanwhile, Stephens maintained an Equalweight rating on the stock, slightly adjusting its price target to $200 from $205.

The consensus among analysts polled by FactSet gives Universal Health an average rating of overweight, with a mean price target of $222.24. This overall positive sentiment from Wall Street appears to be driving today's significant stock price increase, as investors react to the favorable outlook for the company. The strong surge in UHS stock suggests that market participants are aligning their expectations with the analysts' optimistic projections for Universal Health's future growth and profitability.